Loading
Latest filing published 18 May 2020 for Cardiff Oncology, Inc., €19k.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Thomas Adams PhD is a declared insider at 3 companies; the most frequent names are Iris International Inc, Cardiff Oncology, Inc. and Synergy Pharmaceuticals, Inc. Between 3 April 2006 and 14 May 2020, the trades on record add up to 93 filings.
Market trades split into 1 purchase (€19k) and 48 sales (€842k). Sales outweigh purchases by €824k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 27 share grants and 14 option exercises. So far in 2020, the count stands at 1 purchase and no sales.
The record was last updated on 18 May 2020 with an open-market purchase (€19k) in Cardiff Oncology, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 87 declarations